PRE MARKET
The trends on Gift Nifty also indicate a tepid start for the Indian benchmark index. The Gift Nifty was trading around 23,557 level or nearly 17 points.
US stock market ended mixed on Thursday amid progress toward ending the Iran war.
The Dow Jones Industrial Average down 51.23 points, or 0.10%, to 51,509.70, while the S&P 500 gained 30.63 points, or 0.41%, to 7,584.31. The Nasdaq Composite closed 23.02 points, or 0.09%, lower at 26,830.96.
Asian markets traded lower on Friday, following an overnight slump in US tech stocks. Japan’s Nikkei 225 declined 1.37%, while the Topix eased 0.07%. South Korea’s Kospi tanked 6.25%, while the Kosdaq plunged 2.41%. Hong Kong’s Hang Seng index futures indicated a lower opening.
STOCKS IN NEWS
Tata Motors
Chairman N. Chandrasekaran stated that the company should aim to capture more than 20% market share by 2030, provided India’s passenger vehicle market expands to 6 million units by then.
ICICI Bank
The bank said that it has received a warning letter from SEBI in its capacity as a custodian after permitting a foreign portfolio investor (FPI) to repatriate funds before the completion of the mandatory lock-in period prescribed under the Voluntary Retention Route (VRR).
IndiGo
IndiGo has decided to temporarily halt services to six international destinations due to weaker demand and rising cost pressures.
Vedanta
Vedanta said that the Enforcement Directorate (ED) has completed its search operations at certain company locations under the provisions of the Foreign Exchange Management Act (FEMA). The company further clarified that no penalties, restrictions, or sanctions have been levied against it.
Tata Steel
Tata Steel is aiming for nearly 9% growth in domestic steel sales this fiscal year, supported by increased output from its Kalinganagar plant in Odisha as the facility continues to ramp up production, according to media reports.
Aurobindo Pharma
The pharmaceutical company has secured final approval from the US Food and Drug Administration (USFDA) to manufacture and sell Tofacitinib Tablets in 5 mg and 10 mg strengths. The approved tablets are bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xeljanz Tablets, marketed by PF Prism CV.
Source: Mint